Advertisement

Topics

Latest "BIO RELIANCE" News Stories

13:18 EST 18th November 2018 | BioPortfolio

Here are the most relevant search results for "BIO RELIANCE" found in our extensive news archives from over 250 global news sources.

More Information about BIO RELIANCE on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about BIO RELIANCE for you to read. Along with our medical data and news we also list BIO RELIANCE Clinical Trials, which are updated daily. BioPortfolio also has a large database of BIO RELIANCE Companies for you to search.

Showing "RELIANCE" News Articles 1–25 of 595

Friday 16th November 2018

MJardin Group Announces Conference Call to Discuss GrowForce Merger

MJardin Group, Inc. (“MJardin” or the “Company”) (CSE: MJAR), a leader in cannabis management, today announced that it will host a conference call to discuss the recently announced merger (the “Proposed Acquisition”) with GrowForce Holdings Inc. (“GrowForce”) on Monday, November 19, 2018 at 4:00 p.m. Eastern Time. Investors interes...


MorphoSys and I-Mab Sign Strategic Partnering Agreement for MorphoSys's Novel Immuno-Oncology Agent MOR210

SHANGHAI, Nov. 16, 2018 /PRNewswire/ -- MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and I-Mab Biopharma ("I-Mab"), a biotech company focusing exclusively on innovative biologics in immuno-oncology and auto-immune diseases, jointly announced today that they have entered into an exclusive strategic collaboration and regional licensing agreement for MOR21...

Thursday 15th November 2018

MorphoSys and I-Mab Sign Strategic Partnering Agreement for MorphoSys's Novel Immuno-Oncology Agent MOR210 (news with additional features)

DGAP-News: MorphoSys AG / Key word(s): Miscellaneous 15.11.2018 / 22:01 The issuer is solely responsible for the content of this announcement. Planegg/Munich, Germany, November 15, 2018   MorphoSys and I-Mab Sign Strategic Partnering Agreement for MorphoSys's Novel Immuno-Oncology Agent MOR210   MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) ...


Axonics® Granted Seven U.S. Utility Patents Related to its Implantable Sacral Neuromodulation Technology

Axonics Modulation Technologies, Inc., (NASDAQ: AXNX) developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and bowel dysfunction, announced

Ophthalmic Instruments, Inc. Participating in Monterey Fall Symposium of the California Optometric Association

This three day event provides a platform for connecting with hundreds of doctors of optometry IRVINE, Calif. (PRWEB) November 15, 2018 Ophthalmic Instruments, Inc., a leading distributor of quality ophthalmic instruments, today announced its participation in the California Optometric Association’s Monterey Fall Symposium. This three day event will be held November 16-18 at the Monterey Marriott...

TransEnterix Named to Deloitte’s Technology Fast 500

TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between surgeons and patients to improve minimally invasive surgery, today announced its naming to Deloitte’s 2018 Technology Fast 500TM, an annual ranking of the fastest growing North American companies in the technology, media, telecommunications, life sc...

Wednesday 14th November 2018

Reliance On ‘Digitized Paper’ Is Slowing Drug Development – US FDA’s Woodcock

Efficient development and review is being hindered by the inability to exchange data freely and truly capitalize on the digital...    

Innovus Pharma Reports Another New Quarterly Revenue Record of Approximately $7.4 Million for the Third Quarter 2018 and $19.2 Million for the First Nine Months of 2018

The Company is in its Fifth Consecutive Quarter of Net Revenue Growth and Working Diligently Towards Exiting the Fourth Quarter 2018 Profitable Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine ...

Generex Revises Record & Payment Dates for 20:1 Stock Dividend

Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that it has revised the record and payment dates for the previously announced 20:1 common stock dividend. The Record Date for

Express Scripts Creates New Formulary to Lower Drug Costs

NewsNew National Preferred Flex Formulary provides employers and health plans a pathway to cover lower list price products, help deliver lower member out-of-pocket costs, and reduce reliance on brand rebates.

Bio-Rad and the University of Chicago Win Patent Infringement Case Against 10X Genomics Related to Droplet Microfluidics Technologies

A Federal District Court jury yesterday found that 10X Genomics willfully infringed three United States patents owned by the University of Chicago and exclusively licensed to Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products (NYSE: BIO and BIOb). In awarding Bio-Rad $23.9 million in damages, the jury una...

Tuesday 13th November 2018

MEDNAX Announces Closing of $500 Million of 6.250% Senior Notes Due 2027

MEDNAX, Inc. (NYSE:MD), announced today the closing of the previously announced private placement of $500 million aggregate principal amount of its 6.250% senior notes due January 15, 2027 (the “Notes”). The completed transaction resulted in approximately $492.5 million in net proceeds to MEDNAX, which will be used to repay a portion of the indebtednes...

Sproutly Signs LOI with the Largest Caribbean Medical Cannabis Producer to Establish a Joint Venture to Sell Cannabis Infused Beverages and Oil Products

NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICES Sproutly Canada, Inc. (CSE: SPR) (OTCQB: SRUTF) (FSE: 38G) (“Sproutly" or the “Company”) is pleased to announce that it has entered into a letter of intent with Global Canna Labs Limited (“Global Canna Labs”), the Caribbean’s largest medical cannabis producer, to establish a join...

Generex Publishes Update to Pending 20:1 Stock Dividend

Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today released an update on its previously announced 20:1 common stock dividend pending completion of FINRA review. All OTC traded companies are required to file a notice with FINRA of material corporate

FSD Pharma Receives License to Sell to Other Licensed Producers and Expands Growth Production Footprint

FSD Pharma Inc. (“FSD Pharma” or the “Company”) (CSE:HUGE) (OTCQB:FSDDF) (FRA:0K9) announced today that the license of its wholly-owned subsidiary, FV Pharma Inc. (“FV Pharma”) under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) has been migrated to the Cannabis Act and its regulations, effective November 8, 2018. The is...

Bio-Rad Wins USDA Contract for Its Pathogen Detection Testing Products

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that the company has been awarded a contract for iQ-Check real-time PCR pathogen detection test kits and the iQ-Check Prep Automation System from the United States Department of Agriculture’s Food Safety and Inspecti...

NextCure Raises $93 Million in Series B Financing

-- Proceeds Will Advance Growing Portfolio of Novel Immunomedicine Drug Candidates -- NextCure Inc., a privately-held biopharmaceutical company discovering and developing the next generation of immunomedicines for cancer and other diseases, today announced the completion of a $93 million series B

Kiadis Pharma to present at upcoming investor conferences in November 2018

    Kiadis Pharma to present at upcoming investor conferences in November 2018 Amsterdam, The Netherlands, November 13, 2018 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces that it is scheduled to present at the following investor conferences in Novembe...

Monday 12th November 2018

TherapeuticsMD Announces Participation in Three Upcoming Investor Conferences

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that the company will participate in three upcoming healthcare investor conferences. Chief Executive Officer Robert G. Finizio will provide an overview of the company at the conferences. Details for the presentations include: ...

Urovant Sciences Reports Financial Results for the Second Fiscal Quarter Ended September 30, 2018 and Provides Corporate Update

Urovant Sciences Ltd. (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing therapies for urologic conditions, today reported financial results for the three and six months ended September 30, 2018 and announced corporate updates. Recent Business Highlights Completed enrollment in international Phase 3 ...

Did urban planning around the car set the stage for rise in right-wing populism?

Urban planning decisions from decades past are likely a contributing factor to the rise of right-wing populism, a study from the University of Waterloo has found. The study looked at urban planning and voting data from post-World War Two to 2010 outside Toronto, Canada. It found that development patterns that led to the reliance on […]

Friday 9th November 2018

PHI, Inc. Announces Results for the Third Quarter Ended September 30, 2018

PHI, Inc. (The Nasdaq Select Global Market: PHII (voting) PHIIK (non-voting)) today reported financial results for the quarter ended September 30, 2018. Consolidated operating revenues for the quarter ended September 30, 2018 were $168.8 million, compared to $150.2 million for the quarter ended September 30, 2017, an increase of $18.6 million. Oil...

Halo Labs Announces Dispensary Sales for the Month of October

Halo Labs Inc. ("Halo" or the "Company") (NEO:HALO) is pleased to report dispensary sales of approximately US$1.23 million for October 2018. This is an increase of approximately US$353,000 over September 2018. Approximately US$245,000 of the dispensary sales in October was derived from the Company’s first full month of sales to dispen...

Elanix Biotechnologies AG: The Management Board of Elanix Biotechnologies AG will make corrections to its 2017 financial statements due to a fault detection by DPR with regard to the accounting of intangible assets in the 2015 consolidated financial state

Elanix Biotechnologies AG / Key word(s): Miscellaneous Elanix Biotechnologies AG: The Management Board of Elanix Biotechnologies AG will make corrections to its 2017 financial statements due to a fault detection by DPR with regard to the accounting of intangible assets in the 2015 consolidated financial statements 09-Nov-2018 / 11:29 CET/CEST Disclosure of an inside information acc. to Art...

Evolva Business Update

Evolva (SIX: EVE) today provides a quarterly business update, showing a strong underlying dynamic in building the business. The key items are: Product sales Product sales continued a solid growth trend, although sales have shown seasonal effects with summer months being significantly lower compared to the rest of the y...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks